Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuhui Chen

Showing results (81-90 of 112) with videos related to

Pageof 12
Sort By:
Bioorganic & Medicinal Chemistry Letters|May 31, 2022
Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agentZhigang Huang, Wei Luo, Deming Xu, et al.
Bioorganic & Medicinal Chemistry Letters|April 8, 2017
The discovery of tetrahydropyridine analogs as hNav1.7 selective inhibitors for analgesiaWentao Wu, Zhixiang Li, Guangwen Yang, et al.
ACS Infectious Diseases|October 11, 2022
α2,6-Sialylation Is Upregulated in Severe COVID-19, Implicating the Complement CascadeRui Qin, Emma Kurz, Shuhui Chen, et al.
Bioorganic & Medicinal Chemistry Letters|September 2, 2024
Discovery and preclinical profile of YK-2168, a differentiated selective CDK9 inhibitor in clinical developmentYingchun Liu, Zhaobing Xu, Lihong Hu, et al.
Medrxiv : the Preprint Server for Health Sciences|June 15, 2022
α2,6-Sialylation is Upregulated in Severe COVID-19 Implicating the Complement CascadeRui Qin, Emma Kurz, Shuhui Chen, et al.
Antimicrobial Agents and Chemotherapy|April 11, 2022
Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Expression Inhibitor GST-HG131 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation TrialXiaojiao Li, Yusi Liu, Hanxin Yao, et al.
Bioorganic & Medicinal Chemistry Letters|July 1, 2022
Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agentWei Luo, Zhigang Huang, Deming Xu, et al.
Journal of the American Heart Association|December 11, 2025
Murray Law-Based Quantitative Flow Ratio Proficiency in Clinical Practice: Validating Routine Diagnostic Performance and Analyzing Learning Curve ThresholdsDan Deng, Yue Feng, Min Zeng, et al.
Science Advances|January 7, 2022
O-linked α2,3 sialylation defines stem cell populations in breast cancerMelanie R Walker, Hira Lal Goel, Dimpi Mukhopadhyay, et al.
Journal of Cardiovascular Computed Tomography|April 18, 2026
Rationale and design of the MAPS trial: A nationwide multicenter prospective validation of CT-derived index of microcirculatory resistance for precision ischemia managementDan Deng, Chen Wan, Yan Lu, et al.
Pageof 12

Showing results (81-90 of 112) with videos related to

Sort By:
Pageof 12
Bioorganic & Medicinal Chemistry Letters|May 31, 2022
Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agentZhigang Huang, Wei Luo, Deming Xu, et al.
Bioorganic & Medicinal Chemistry Letters|April 8, 2017
The discovery of tetrahydropyridine analogs as hNav1.7 selective inhibitors for analgesiaWentao Wu, Zhixiang Li, Guangwen Yang, et al.
ACS Infectious Diseases|October 11, 2022
α2,6-Sialylation Is Upregulated in Severe COVID-19, Implicating the Complement CascadeRui Qin, Emma Kurz, Shuhui Chen, et al.
Bioorganic & Medicinal Chemistry Letters|September 2, 2024
Discovery and preclinical profile of YK-2168, a differentiated selective CDK9 inhibitor in clinical developmentYingchun Liu, Zhaobing Xu, Lihong Hu, et al.
Medrxiv : the Preprint Server for Health Sciences|June 15, 2022
α2,6-Sialylation is Upregulated in Severe COVID-19 Implicating the Complement CascadeRui Qin, Emma Kurz, Shuhui Chen, et al.
Antimicrobial Agents and Chemotherapy|April 11, 2022
Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Expression Inhibitor GST-HG131 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation TrialXiaojiao Li, Yusi Liu, Hanxin Yao, et al.
Bioorganic & Medicinal Chemistry Letters|July 1, 2022
Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agentWei Luo, Zhigang Huang, Deming Xu, et al.
Journal of the American Heart Association|December 11, 2025
Murray Law-Based Quantitative Flow Ratio Proficiency in Clinical Practice: Validating Routine Diagnostic Performance and Analyzing Learning Curve ThresholdsDan Deng, Yue Feng, Min Zeng, et al.
Science Advances|January 7, 2022
O-linked α2,3 sialylation defines stem cell populations in breast cancerMelanie R Walker, Hira Lal Goel, Dimpi Mukhopadhyay, et al.
Journal of Cardiovascular Computed Tomography|April 18, 2026
Rationale and design of the MAPS trial: A nationwide multicenter prospective validation of CT-derived index of microcirculatory resistance for precision ischemia managementDan Deng, Chen Wan, Yan Lu, et al.
Pageof 12